S&P 500   3,121.20 (-0.03%)
DOW   27,939.24 (-0.35%)
QQQ   203.42 (+0.17%)
CGC   14.98 (+5.34%)
BABA   184.27 (-0.18%)
T   38.09 (-3.89%)
ACB   2.32 (+1.75%)
F   8.92 (-0.34%)
BAC   32.96 (+0.00%)
DIS   148.96 (+0.89%)
S&P 500   3,121.20 (-0.03%)
DOW   27,939.24 (-0.35%)
QQQ   203.42 (+0.17%)
CGC   14.98 (+5.34%)
BABA   184.27 (-0.18%)
T   38.09 (-3.89%)
ACB   2.32 (+1.75%)
F   8.92 (-0.34%)
BAC   32.96 (+0.00%)
DIS   148.96 (+0.89%)
S&P 500   3,121.20 (-0.03%)
DOW   27,939.24 (-0.35%)
QQQ   203.42 (+0.17%)
CGC   14.98 (+5.34%)
BABA   184.27 (-0.18%)
T   38.09 (-3.89%)
ACB   2.32 (+1.75%)
F   8.92 (-0.34%)
BAC   32.96 (+0.00%)
DIS   148.96 (+0.89%)
S&P 500   3,121.20 (-0.03%)
DOW   27,939.24 (-0.35%)
QQQ   203.42 (+0.17%)
CGC   14.98 (+5.34%)
BABA   184.27 (-0.18%)
T   38.09 (-3.89%)
ACB   2.32 (+1.75%)
F   8.92 (-0.34%)
BAC   32.96 (+0.00%)
DIS   148.96 (+0.89%)
Log in

Insulet Stock Price, Forecast & Analysis (NASDAQ:PODD)

$181.92
-0.57 (-0.31 %)
(As of 11/19/2019 01:32 PM ET)
Today's Range
$180.63
Now: $181.92
$182.99
50-Day Range
$144.66
MA: $157.67
$183.02
52-Week Range
$70.80
Now: $181.92
$184.04
Volume22,910 shs
Average Volume811,669 shs
Market Capitalization$11.25 billion
P/E Ratio3,638.40
Dividend YieldN/A
Beta0.96
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:PODD
CUSIP45784P10
Phone978-600-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$563.82 million
Cash Flow$0.32 per share
Book Value$3.59 per share

Profitability

Net Income$3.29 million

Miscellaneous

Employees1,169
Market Cap$11.25 billion
Next Earnings Date2/24/2020 (Estimated)
OptionableOptionable

Receive PODD News and Ratings via Email

Sign-up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.


Insulet (NASDAQ:PODD) Frequently Asked Questions

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) posted its quarterly earnings results on Tuesday, November, 5th. The medical instruments supplier reported $0.01 EPS for the quarter, missing the Zacks' consensus estimate of $0.03 by $0.02. The medical instruments supplier had revenue of $192.12 million for the quarter, compared to analysts' expectations of $179.50 million. Insulet had a net margin of 2.38% and a return on equity of 10.34%. The company's quarterly revenue was up 27.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.03 EPS. View Insulet's Earnings History.

When is Insulet's next earnings date?

Insulet is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Insulet.

What price target have analysts set for PODD?

17 equities research analysts have issued twelve-month price objectives for Insulet's stock. Their forecasts range from $100.00 to $200.00. On average, they expect Insulet's stock price to reach $153.47 in the next twelve months. This suggests that the stock has a possible downside of 15.7%. View Analyst Price Targets for Insulet.

What is the consensus analysts' recommendation for Insulet?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 8 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insulet.

Has Insulet been receiving favorable news coverage?

News headlines about PODD stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Insulet earned a news sentiment score of 1.1 on InfoTrie's scale. They also assigned headlines about the medical instruments supplier a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Insulet.

Are investors shorting Insulet?

Insulet saw a increase in short interest in October. As of October 15th, there was short interest totalling 5,230,000 shares, an increase of 11.0% from the September 15th total of 4,710,000 shares. Based on an average daily trading volume, of 959,900 shares, the short-interest ratio is presently 5.4 days. Approximately 8.8% of the company's shares are short sold. View Insulet's Current Options Chain.

Who are some of Insulet's key competitors?

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include DexCom (DXCM), Alibaba Group (BABA), NVIDIA (NVDA), Tandem Diabetes Care (TNDM), Netflix (NFLX), Splunk (SPLK), salesforce.com (CRM), ServiceNow (NOW), Roku (ROKU) and Veeva Systems (VEEV).

Who are Insulet's key executives?

Insulet's management team includes the folowing people:
  • Ms. Shacey Petrovic, Pres, CEO & Director (Age 45)
  • Mr. Charles Alpuche, Exec. VP & COO (Age 59)
  • Mr. Bret Christensen, Exec. VP & Chief Commercial Officer (Age 47)
  • Mr. Patrick J. Sullivan, Consultant (Age 67)
  • Mr. Michael L. Levitz, Advisor (Age 45)

Who are Insulet's major shareholders?

Insulet's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Eagle Asset Management Inc. (1.18%), Carillon Tower Advisers Inc. (0.87%), KAMES CAPITAL plc (0.62%), First Trust Advisors LP (0.43%), Columbus Circle Investors (0.38%) and Russell Investments Group Ltd. (0.33%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Institutional Ownership Trends for Insulet.

Which institutional investors are selling Insulet stock?

PODD stock was sold by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, KAMES CAPITAL plc, Chartwell Investment Partners LLC, C WorldWide Group Holding A S, Russell Investments Group Ltd., SG Americas Securities LLC, Essex Investment Management Co. LLC and Triodos Investment Management BV. Company insiders that have sold Insulet company stock in the last year include Aiman Abdel-Malek, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Insider Buying and Selling for Insulet.

Which institutional investors are buying Insulet stock?

PODD stock was bought by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Carillon Tower Advisers Inc., First Trust Advisors LP, Jag Capital Management LLC, Columbus Circle Investors, State of New Jersey Common Pension Fund D, California Public Employees Retirement System and Handelsbanken Fonder AB. View Insider Buying and Selling for Insulet.

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $182.10.

How big of a company is Insulet?

Insulet has a market capitalization of $11.26 billion and generates $563.82 million in revenue each year. The medical instruments supplier earns $3.29 million in net income (profit) each year or $0.05 on an earnings per share basis. Insulet employs 1,169 workers across the globe.View Additional Information About Insulet.

What is Insulet's official website?

The official website for Insulet is http://www.insulet.com/.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]


MarketBeat Community Rating for Insulet (NASDAQ PODD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  601 (Vote Outperform)
Underperform Votes:  527 (Vote Underperform)
Total Votes:  1,128
MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote "Outperform" if you believe PODD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PODD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel